OmniSeq, a Roswell Park Cancer Institute spinoff company, has appointed Mark Gardner as chief executive officer.
He is currently vice president and general manager for Thermo Fisher’s Next Generation Clinical Sequencing business, where he oversees sales, product management, marketing and research and development.
OmniSeq is the largest commercial venture ever for Roswell Park. The institute has invested more than $25 million to develop the test tailored to the unique genetic characteristics of patients. The new test lets doctors customize lung cancer treatment to a patient’s tumor and the underlying molecular changes causing the cancer, and work is under way to extend it to other cancers.